Evidence map›Paper›PMID 38402640›Full record

ArticleCancer science2024

Integration of CD4

Ge Liu, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Bingyu Li, Jingtong Xu, Hailong Liu, Yuan Chang, Yu Zhu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
  3. Article
  4. Integration of CD4Cancer science · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Ge LiuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kaifeng JinNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei LiuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xiaohe SuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ziyue XuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Bingyu LiDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jingtong XuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiwei WangDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-3494-3114
Fudan University · CNShanghai Jiao Tong University · CNFudan University Shanghai Cancer Center · CNSun Yat-sen University · CN

Funding

China Postdoctoral Science Foundation BX20230091Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation YJYQ201802National Natural Science Foundation of China 82002670National Natural Science Foundation of China 82103408National Natural Science Foundation of China 82272930National Natural Science Foundation of China 82372793National Natural Science Foundation of China 82373276Shanghai Anticancer Association EYAS PROJECT SACA-CY22B02Shanghai Anticancer Association EYAS PROJECT ZYJH202309Shanghai Municipal Health Bureau Project 20224Y0232Shanghai Municipal Health Bureau Project 202340127Shanghai Municipal Health Bureau Project 202340195Shanghai Municipal Natural Science Foundation 22ZR1413400Shanghai Municipal Natural Science Foundation 23ZR1411700Shanghai Municipal Natural Science Foundation 23ZR1440300Shanghai Sailing Program 21YF1407000
6 · The paper itself

Abstract

Muscle-invasive bladder cancer (MIBC) is a disease characterized by molecular and clinical heterogeneity, posing challenges in selecting the most appropriate treatment in clinical settings. Considering the significant role of CD4

Indexed as

B7-H1 AntigenUrinary Bladder NeoplasmsCD4-Positive T-LymphocytesHumansMusclesPrognosisT-LymphocytesTumor MicroenvironmentB7-H1 AntigenCD4+ T cellsimmune‐molecular subtypeimmunotherapymuscle‐invasive bladder cancerplatinum‐based chemotherapy

Identifiers

PMID38402640
PMCPMC11007017
OpenAlexW4392142376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.